

Appendices

Appendix 1 - Figure 1. Case Definition

Appendix 2 - Figure 2. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with recent use of (top panel) and past use (bottom panel) of domperidone compared to no use.


Appendix 3 - Figure 3. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exposure measured in the 60 days prior to index date.



Appendix 4 - Figure 4. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use, adjusting for covariates measured 366 to 730 days before index date.

Appendix 5 - Figure 5. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use, adjusting for covariates measured in the year before cohort entry.

Appendix 6 - Figure 6. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exclusion of patients with long hospital stay.


Appendix 7 - Figure 7. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exclusion of unattended death.






Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 2. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with recent use of (top panel) and past use (bottom panel) of domperidone compared to no use.




Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 3. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exposure measured in the 60 days prior to index date.




Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 4. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use, adjusting for covariates measured 366 to 730 days before index date.




Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 5. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use, adjusting for covariates measured in the year before cohort entry.



Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 6. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exclusion of patients with long hospital stay.



Small cells (count \leq 5) were suppressed by participating sites due to privacy restrictions
 CPRD, Clinical practice research datalink

Appendix Figure 7. Adjusted rate ratios of ventricular tachyarrhythmia/sudden cardiac death associated with current use of domperidone compared to no use. Exclusion of unattended death.